# Lyvgen Biopharma Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lyvgen-biopharma-co

- Industry: Healthcare Specialists
- Headquarters: Shanghai, China
- Website: www.lyvgen.com
- Total disclosed funding: $30M
- Latest round: Series C (Feb 23, 2021)
- Investors on record: 8

## About

Lyvgen Biopharma Co., Ltd focuses on developing innovative immuno-oncology therapeutics that activate the body’s immune response against tumors. Their advanced monoclonal antibodies aim to enhance cancer treatment efficacy.Founded in 2016, Lyvgen Biopharma Co., Ltd is based in Shanghai, China, specializing in immuno-oncology therapeutics. The company has closed two funding deals, with the latest being a Series B round on February 23, 2021, raising USD 30.00 mn led by 6 Dimensions Capital. Jieyi Wang serves as the CEO of the company, guiding its strategic direction.Lyvgen Biopharma specializes in the development of innovative immuno-oncology therapeutics, focusing on tumor-targeted immune activation through a proprietary platform known as xLinkAb. The company's primary offerings include next-generation monoclonal antibodies such as LVGN6051, LVGN7409, and LVGN3616. LVGN6051 is designed to enhance the proliferation and cytotoxicity of antitumor immune cells by utilizing crosslinking-dependent CD137 agonistic activity, achieving an optimal efficacy and safety profile. LVGN7409 activates CD40 to promote tumor antigen presentation and enhance the immune response, effectively transforming the immune 'cold' tumor microenvironment into a more responsive state. LVGN3616 serves to block the PD-1 pathway, thereby amplifying immune responses against cancer. These products are aimed at oncologists and research institutions, with the therapeutic solutions primarily targeting markets in North America, Europe, and parts of Asia.Lyvgen Biopharma engages in business transactions primarily through partnerships and collaborations with healthcare providers, research institutions, and pharmaceutical companies. The revenue model involves revenue-sharing agreements and potential milestone payments connected to the advancement of their proprietary products through clinical trials and regulatory approvals. Flagship products such as LVGN6051 and LVGN7409 may be offered under specific pricing plans that reflect their unique applications in oncology treatment. The company’s revenue structure includes B2B transactions, focusing on partnerships that facilitate the distribution of their monoclonal antibodies to healthcare providers and specialty pharmacies, ensuring that these innovative therapies reach the intended end-users effectively.Lyvgen Biopharma plans to leverage the funds raised in its most recent Series B round to support the development and launch of new products, including advancements in their monoclonal antibody lineup. The company is also targeting expansion into additional markets, particularly in Europe and North America, by 2023. In February 2021, the company raised USD 30.00 mn in funding led by IDG Capital, with participation from ChuangVest Ventures, FTZ Fund, and Suzhou Longmen Venture Capital, which will aid in accelerating their clinical trials and market entry strategies.

## Funding rounds

- Series C, Feb 23, 2021 — IDG Capital, ChuangVest Ventures, FTZ Fund, Suzhou Longmen Venture Capital
- Series B, Jul 17, 2018, $30M — 5Y Capital, 6 Dimensions Capital, Haoling Investment Management, Winfair Global

## Investors

- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series B
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series B
- Haoling Investment Management (https://capitalatlas.ai/funds/haoling-investment-management) — Series B
- Winfair Global — Series B
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series C
- ChuangVest Ventures (https://capitalatlas.ai/funds/chuangvest-ventures) — Series C
- FTZ Fund (https://capitalatlas.ai/funds/ftz-fund) — Series C
- Suzhou Longmen Venture Capital (https://capitalatlas.ai/funds/suzhou-longmen-venture-capital) — Series C